FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/Tirzepatide Trial Explores New Horizons in Smoking Cessation and Weight Management
Retour à la bibliothèque de recherche

Tirzepatide Trial Explores New Horizons in Smoking Cessation and Weight Management

May 25, 2026
Share
Recherche émergente

Basé sur des recherches émergentes. Ces découvertes sont prometteuses mais nécessitent une validation supplémentaire.

À propos de cette analyse

Cet article est un résumé AI-assisté d'un élément de presse ou d'une annonce clinique récemment publié. Il vise à fournir une vue d'ensemble rapide et accessible pour la communauté de recherche en peptides. Pour une précision totale, consultez toujours l'original source ci-dessous.

Tirzepatide Trial Explores New Horizons in Smoking Cessation and Weight Management

A groundbreaking multi-site clinical trial is set to explore the potential of tirzepatide, a promising peptide therapy, for aiding smoking cessation among individuals with overweight or obesity. This Phase 2 study, sponsored by the University of Southern California, aims to provide valuable insights into how this innovative treatment might help smokers quit and manage weight gain after quitting.

Background

Tirzepatide is an emerging therapeutic agent that has shown promising results in managing diabetes and obesity. It works by mimicking the effects of two naturally occurring hormones: GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory polypeptide). These peptides play a crucial role in regulating appetite, blood sugar levels, and weight management. Given these properties, researchers are now investigating whether tirzepatide can also be effective for smoking cessation, especially considering that many smokers struggle with both addiction and weight concerns.

Smoking is one of the leading preventable causes of death worldwide, contributing significantly to various health issues such as lung cancer, heart disease, and respiratory disorders. While numerous treatments exist to help individuals quit smoking, there remains a need for more effective interventions, particularly those addressing the dual challenges of nicotine dependence and weight gain post-cessation.

Key Details

The clinical trial, titled "Multi-Site Trial of Tirzepatide for Smoking Cessation" (NCT07602699), plans to recruit 300 participants from four major academic medical centers across the United States: University of Southern California, Yale University, University of Chicago, and the University of Colorado Anschutz Medical Campus. Participants will have a body mass index (BMI) of at least 25 kg/m², indicating overweight or obesity.

The trial's primary objective is to assess the efficacy of tirzepatide in helping people who smoke quit their habit. Secondary goals include evaluating its impact on post-cessation weight gain and other smoking-related behaviors. Participants will be randomly assigned either tirzepatide or a placebo, allowing researchers to compare outcomes between the two groups.

This study represents an important step forward in understanding how peptide therapy can address multiple health issues simultaneously. By targeting both smoking cessation and weight management, this research could potentially offer a comprehensive solution for individuals struggling with these interconnected challenges.

Key Takeaways

  • Innovative Approach: The trial explores using tirzepatide to tackle smoking addiction alongside obesity concerns.
  • Multi-Site Collaboration: Researchers from four prestigious universities are collaborating on this groundbreaking study.
  • Dual Focus: The primary aim is to help people quit smoking, while also managing post-cessation weight gain effectively.
  • Regulatory Relevance: This trial could pave the way for new FDA-approved treatments that address multiple health issues at once.

What This Means

For the peptide community, this study represents a significant advancement in exploring the multifaceted benefits of peptide therapy. It highlights how peptides like tirzepatide can be harnessed to manage complex conditions involving both behavioral and physiological aspects. As more research uncovers the potential applications of these therapies, we may see broader acceptance and integration into mainstream healthcare practices.

---

Source: ClinicalTrials.gov — Published 18 May 2026

This article is for informational purposes only and does not constitute medical advice.

Note de l'éditeur

Cette analyse a été générée à l'aide d'outils AI et revue par le service éditorial de Peptide Contacts. Bien que nous nous efforcions de maintenir une précision, le contenu généré par l'IA peut contenir des erreurs ou des omissions. Nous encourageons les lecteurs à vérifier les informations auprès de l'original source. source originale pour des détails complets, méthodologie et données.

Peptide Contacts fournit des résumés de recherche curatisés pour des fins d'information uniquement. Ce contenu ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant de prendre toute décision concernant votre santé.

Comments

Sign in to join the discussion

Cet article a été généré à l'aide d'IA et peut contenir des inexactitudes. Il est fourni pour des fins d'information uniquement et ne constitue pas un avis médical. Vérifiez toujours les informations auprès de l'original source et consultez un fournisseur de soins de santé qualifié avant de prendre toute décision concernant votre santé.